Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy

Eşkazan, Ahmet Emre; Soysal, Teoman; Öngören, Şeniz; Gültürk, Emine; Ferhanoğlu, Burhan; Aydın, Yıldız

doi:10.3324/haematol.2011.040048

Cited by 25 publications

(20 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, adverse events may accumulate over time (also pleural effusions) or may be related to a certain dose of BCR/ABL1 inhibitors. With regard to dasatinib-induced pleural effusions, we can now state that lowering the dose of dasatinib does at least not eliminate the risk for development of clinically relevant effusions, as confirmed by Ahmet Emre Eskazan et al 1 The reason for this phenomenon (low-dose dasatinib-induced effusion) remains unknown. One explanation would be that lowdose dasatinib is still capable of promoting the activation of certain immune cells that release vasoactive mediators in tissues.…”

Section: 8mentioning

confidence: 80%

See 1 more Smart Citation

Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors

Valent¹

2011

Haematologica

View full text Add to dashboard Cite

Section: 8mentioning

confidence: 80%

“…The study of Ahmet Emre Eskazan 1 suggests that CML patients treated with lowdose dasatinib (100 mg daily) may develop pleural effusions at a higher frequency than that reported in published clinical trials.…”

mentioning

confidence: 85%

Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors

Valent¹

2011

Haematologica

View full text Add to dashboard Cite

“…Эффективность и безопасность ИТК2 в качестве первой и второй линий терапии хронической фазы ХМЛ широко изучены в рамках клинических исследований [10][11][12][13][14][15][16][17][18][19]. Однако в них предусмотрено большое число ограни-чений включения, которые описаны в литературе.…”

Section: Discussionunclassified

“…Он относится к ИТК2 и может применяться у больных ХМЛ в хронической фазе как в первой, так и последующих линиях терапии. Данные об эффективности и безопасности дазатиниба представ-лены в ряде крупных международных исследований, включая DASISION и START-C [10][11][12][13][14][15][16][17][18][19].…”

Section: Introductionunclassified

Dasatinib in Firstand Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Ионова

Булиева

Vinogradova

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving Dasatinib” (20122015) and “Quality of Life and Symptom Profile in Imatinib-Resistant or Intolerant Patients with Chronic Myeloid Leukemia” (2011-2014). Methods. Data of 107 patients with chronic myeloid leukemia in chronic phase were involved in the real-world analysis - 32 newly diagnosed patients on first-line treatment with dasatinib or after yearly switch to dasatinib after ima-tinib treatment failure and 75 imatinib-resistant or intolerant patients on second-line treatment with dasatinib. Treatment effectiveness and safety of dasatinib were assessed during first- and second-line dasatinib treatment using clinical outcomes as well as quality of life and symptom profile assessment. Results. The real-world data obtained during observational study in limited population of CML patients conform the results of clinical trials devoted to evaluation of treatment efficacy and safety of dasatinib treatment in first- and second-line treatment and demonstrate the importance of patient-reported outcomes. Patient's quality of life improved within 12 months of the first-line dasatinib therapy according to the following scales: role physical functioning, pain, vitality, social functioning and role emotional functioning. The most pronounced and clinically significant improvement was observed for the role emotional functioning (51.1 vs. 68.9). During the second-line dasatinib treatment, stabilization of quality of life parameters was registered for the following scales: vitality, social functioning, mental health, and pain. Significant improvement of the Integral Quality of Life Index was observed (p < 0.05). Positive dynamics of relevant symptoms was registered. The symptom severity decreased during both the first- and second-line therapy. Conclusion. Quality of life and symptom assessment in CML patients contribute to a better disease control in accordance with the principles of risk-adaptive therapy.

show abstract

“…9 However, even in patients receiving 100 mg once daily, pleural effusions develop and may accumulate over time. 12,13 Nilotinib-treated patients may develop increases in pancreatic enzymes, bilirubin, and fasting glucose level (Table 1). 5,14,15 Other non-hematologic adverse events include diarrhea, a folliculitis-like skin rash, and bleeding.…”

Section: The Unique Adverse Event Profile Of Nilotinib and Dasatinibmentioning

confidence: 99%

Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities

Valent¹

2011

Haematologica

View full text Add to dashboard Cite

Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy

Cited by 25 publications

References 5 publications

Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors

Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors

Dasatinib in Firstand Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities

Contact Info

Product

Resources

About